Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue: 2018-2025

Historic Non-Current Deffered Revenue for Dianthus Therapeutics (DNTH) over the last 4 years, with Sep 2025 value amounting to $6.1 million.

  • Dianthus Therapeutics' Non-Current Deffered Revenue rose 848.12% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 848.12%. This contributed to the annual value of $1.9 million for FY2024, which is 159.24% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Non-Current Deffered Revenue of $6.1 million as of Q3 2025, which was up 239.94% from $1.8 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Non-Current Deffered Revenue high stood at $6.1 million for Q3 2025, and its period low was $640,000 during Q3 2024.
  • For the 3-year period, Dianthus Therapeutics' Non-Current Deffered Revenue averaged around $1.7 million, with its median value being $745,000 (2023).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first dropped by 14.09% in 2024, then skyrocketed by 848.12% in 2025.
  • Dianthus Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $791,000 in 2022, then decreased by 6.95% to $736,000 in 2023, then soared by 159.24% to $1.9 million in 2024, then spiked by 848.12% to $6.1 million in 2025.
  • Its Non-Current Deffered Revenue stands at $6.1 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.9 million for Q1 2025.